Sanofi Receives CDSCO Approval for Qfitlia Therapy to Prevent Bleeding in Haemophilia Patients
Sanofi Healthcare has received approval from India's Central Drugs Standard Control Organisation (CDSCO) for Qfitlia (Fitusiran), a therapy to prevent bleeding in haemophilia patients aged 12 and older. The treatment, requiring as few as six injections annually, targets both Haemophilia A and B patients, with or without factor VIII or IX inhibitors. Approval was based on positive results from the ATLAS phase 3 clinical trials. This development aims to improve access to prophylactic treatment for haemophilia in India.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 41/100.
Outlets measured: economictimes, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 21 Oct, 09:45 am. Other outlets followed.